Email this article Some aspects of the angiotensin-converting enzyme for leukemias
- Authors: Orlova M.A.1,2, Orlov A.P.1
-
Affiliations:
- Department of Chemistry, M. V. Lomonosov Moscow State University
- Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology, and Immunology
- Issue: Vol 65, No 5 (2016)
- Pages: 1380-1382
- Section: Brief Communications
- URL: https://journals.rcsi.science/1066-5285/article/view/238356
- DOI: https://doi.org/10.1007/s11172-016-1466-0
- ID: 238356
Cite item
Open Access
Access granted
Subscription Access
Abstract
The present article shows the diagnosis of different type leukemias in children by the activity of angiotensin-converting enzyme in blood serum to be not promising. Beside that, enalaprilat, carboxylate inhibitor of ACE, exhibited no specific cytotoxic activity against cancer cells; moreover, in the case of chronic myeloleukemia (K-562) and T-cell acute lymphoblastic leukemia (MOLT-4), its weak protective action against cancer cells was noted.
About the authors
M. A. Orlova
Department of Chemistry, M. V. Lomonosov Moscow State University; Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology, and Immunology
Author for correspondence.
Email: orlova.radiochem@mail.ru
Russian Federation, Build. 3, 1 Leninskie Gory, Moscow, 119992; 1 ul. Samory Mashela, Moscow, 117997
A. P. Orlov
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: orlova.radiochem@mail.ru
Russian Federation, Build. 3, 1 Leninskie Gory, Moscow, 119992
